MANAGEMENT

Michael Beckloff served as Azurity’s Chief Development Officer from May, 2019 until January 2023 when he transitioned to his current role where he continues to work with the Executive Team and Board of Directors as a scientific and technical advisor.
 

Michael was a Co-Founder and served as Chief Development Officer of Silvergate Pharmaceuticals. Silvergate Pharmaceuticals was later acquired and became Azurity Pharmaceuticals. He has more than 40 years of experience in the pharmaceutical, biologics, and medical device industries, with a focus on product development and regulatory sciences. His earlier company, Beckloff Associates, a preeminent global consulting group, employed over 100 pharmaceutical and regulatory scientists, providing service to over 200 clients worldwide. He has worked on numerous approved NDAs, ANDA, and MAAs.

Cardinal Health acquired Beckloff Associates in 2004, where Michael continued until co-founding Silvergate Pharmaceuticals where he focused on developing and delivering high-quality pediatric drug products.

Michael received his Cellular Biology Degree from the University of Kansas.